知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.029 秒)

    Administration of an anti-obesity compound to individuals with renal impairment
    2.
    发明授权
    Administration of an anti-obesity compound to individuals with renal impairment 有权
    向患有肾损伤的个体施用抗肥胖化合物

    公开(公告)号：US08999970B2

    公开(公告)日：2015-04-07

    申请号：US13511639

    申请日：2011-08-31

    申请人： Christen M. Anderson ,  William R. Shanahan

    发明人： Christen M. Anderson ,  William R. Shanahan

    IPC分类号： A61K31/55 ,  G01N33/70

    CPC分类号： A61K31/55 ,  A61K9/0053 ,  G01N33/70 ,  Y10T436/147777

    摘要： The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.

    摘要翻译： 本公开内容涉及通过确定个体的肾功能水平并开出或施用治疗有效量的（R）-8-氯-1-甲基-2,3， 4,5-四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂化物或水合物，条件是个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤， 和中度肾损伤。 此外，本公开涉及用（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂或其药学上可接受的盐，溶剂化物 或水合物从多个需要体重管理的个体中确定个体的肾功能水平，并选择个体用（R）-8-氯-1-甲基-2,3,4,5-四氢 - 四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂化物或水合物，如果个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤和中度肾损伤。

    5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL
    4.
    发明申请
    5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL 审中-公开
    5-HT2C受体拮抗剂通过降低肾上腺素水平来治疗疾病

    公开(公告)号：US20130267500A1

    公开(公告)日：2013-10-10

    申请号：US13820073

    申请日：2011-08-31

    申请人： Christen M. Anderson ,  William R. Shanahan

    发明人： Christen M. Anderson ,  William R. Shanahan

    IPC分类号： A61K31/55

    CPC分类号： A61K31/55 ,  A61K31/00

    摘要： Uses of 5-HT2C receptor agonists in the treatment of disorders ameliorated by reduction of an individual's norepinephrine level, wherein said disorders include but are not limited to hypernorepinephrinemia, cardiomyopathy, cardiac hypertrophy, cardiomyocyte hypertrophy in post-myocardial infarction remodeling, elevated heart rate, vasoconstriction, acute pulmonary vasoconstriction, hypertension, heart failure, cardiac dysfunction after stroke, cardiac arrhythmia, metabolic syndrome, abnormal lipid metabolism, hyperthermia, Cushing syndrome, pheochromocytoma, epilepsy, obstructive sleep apnea, insomnia, glaucoma, osteoarthritis, rheumatoid arthritis, and asthma.

    摘要翻译： 5-HT 2C受体激动剂在治疗通过减少个体去甲肾上腺素水平而改善的病症中的用途，其中所述疾病包括但不限于高肾上腺素肾血症，心肌病，心脏肥大，心肌梗塞后心肌重塑中的心肌细胞肥大，心率升高， 血管收缩，急性肺血管收缩，高血压，心力衰竭，卒中后心脏功能障碍，心律失常，代谢综合征，脂代谢异常，高热，库兴综合征，嗜铬细胞瘤，癫痫，阻塞性睡眠呼吸暂停，失眠，青光眼，骨关节炎，类风湿性关节炎和哮喘 。

    Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
    7.
    发明授权
    Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus 失效

    公开(公告)号：US06653094B2

    公开(公告)日：2003-11-25

    申请号：US09924313

    申请日：2001-08-07

    申请人： Christen M. Anderson ,  Robert E. Davis

    发明人： Christen M. Anderson ,  Robert E. Davis

    IPC分类号： C12Q132

    CPC分类号： C12Q1/6883 ,  G01N33/6893 ,  G01N2800/042

    摘要： The present invention relates to improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

    Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
    8.
    发明授权
    Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus 失效
    线粒体功能改变的指标，用于确定2型糖尿病风险的预测方法

    公开(公告)号：US06280966B1

    公开(公告)日：2001-08-28

    申请号：US09521407

    申请日：2000-03-08

    申请人： Christen M. Anderson ,  Robert E. Davis

    发明人： Christen M. Anderson ,  Robert E. Davis

    IPC分类号： C12Q132

    CPC分类号： C12Q1/6883 ,  G01N33/6893 ,  G01N2800/042

    摘要： The present invention relates to improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, celullar responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

    摘要翻译： 本发明涉及用于早期检测人类发展中的2型糖尿病的风险的改进的诊断方法，以及用于治疗2型糖尿病的治疗药物的筛选测定法，通过比较一种或多种改变的 线粒体功能。 改变线粒体功能的指标包括线粒体酶和ATP生物合成因子等酶。 线粒体功能改变的其他指标包括线粒体质量，线粒体数量和线粒体DNA含量，细胞内钙升高和凋亡细胞的纤溶酶反应以及自由基生成。 还提供了用于治疗和分层人类患者的方法，这些方法涉及公开的改变的脑膜功能指标。